Brief: Tonix Reports Positive Pre-IND FDA Meeting for TNX-102 SL in Major Depressive Disorder Treatment
18/09/2025 13:08
Sept 18 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TONIX PHARMACEUTICALS HOLDING CORP - PLANS SNDA FOR TNX-102 SL TO INCLUDE MDD TONIX PHARMACEUTICALS HOLDING CORP - IND FILING FOR TNX-102 SL PLANNED FOR Q4 2025 Source text: ID:nGNX4xqxJr Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview